Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely poor prognosis.

New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a type of brain tumor with a dismal prognosis.

A common human virus may prove useful in attacking the deadliest form of brain tumors, according to study conducted by researchers at Duke's Preston Robert Tisch Brain Tumor Center. The researchers said the finding is an important step in developing a vaccine that can attack the tumors by enlisting the help of the body's immune system.

A vaccine that has significantly increased life expectancy in early tests of patients with glioblastoma multiforme (GBM) − the most common, most aggressive form of brain cancer in adults − is now being offered through a clinical trial at Mayo Clinic in Jacksonville.

North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic in Rochester, Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme. These findings were presented today at the American Society of Clinical Oncology Annual Meeting by Eva Galanis, M.D. a Mayo Clinic oncologist and lead investigator of the study.

New early data showed that an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields -- called Tumor-Treating Fields (TTFields) - more than doubled the median overall survival rates in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor.